AUSTEDO (deutetrabenazine) by Teva is huntington's disease is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. Approved for tardive dyskinesia, huntington disease. First approved in 2017.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AUSTEDO (deutetrabenazine) is an oral tablet approved by the FDA in August 2017 for the treatment of Huntington's disease. It is a reversible monoamine depleter that works by inhibiting VMAT2, reducing the uptake of monoamines (dopamine, serotonin, norepinephrine, histamine) into synaptic vesicles and depleting monoamine stores in nerve terminals. The mechanism is believed to address the underlying pathophysiology of involuntary movements associated with Huntington's disease. AUSTEDO represents a deuterated reformulation of tetrabenazine, offering potential pharmacokinetic advantages.
Huntington's disease is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. The major circulating metabolites (α-dihydrotetrabenazine [HTBZ] and β-HTBZ) of deutetrabenazine, are…
Worked on AUSTEDO at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$1.1B Medicare spend — this is a commercially significant brand
AUSTEDO supports roles including brand management, medical science liaisons (MSLs), field sales representatives, and regulatory affairs specialists focused on rare disease commercialization. Success in this space requires deep expertise in Huntington's disease pathophysiology, relationships with specialized neurology centers, and understanding of rare disease patient advocacy and reimbursement. Currently, there are zero linked job openings associated with this product in the provided dataset.